UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...

For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment per institutional guidelines, including hormone replacement as clinically indicated. Withhold or permanently discontinue ...

The results of this review will directly inform BMJ Rapid Recommendation clinical practice guideline recommendation ... children (excluding premature infants due to higher rates of adrenal ...

The US Food and Drug Administration has approved Crinecerfont for treatment of classic congenital adrenal hyperplasia, ...

Adrenal insufficiency or bilateral oophorectomy ... include transdermal testosterone or oral dehydroepiandrosterone treatment, both of which have been shown to result in significant improvements ...

AstraZeneca's supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive ...

Patients with adrenal insufficiency face heightened risks for cardiovascular disease and mortality, largely due to chronic treatment with exogenous glucocorticoids. Although these medications manage ...

In patients who have received less than 14 days of dexamethasone therapy, treatment may be abruptly ... therapy evolved to prevent adrenal insufficiency syndrome and recurrence or exacerbation ...

New guidelines on the diagnosis and management of premature ovarian insufficiency (POI)—developed by the Center for Research Excellence in Women's Health in Reproductive Life (CRE-WHiRL) at Monash ...